top of page
Global Trends in R&D: Overview through 2021
Wed, Mar 30
|Webinar
New medicines are reaching more patients around the world. The healthcare sector has managed to adapt and re-focus during a challenging period to offer effective vaccines and therapeutics and rise to operational and organizational challenges in pursuit of this innovation.
Registration is closed
See other events
Time & Location
Mar 30, 2022, 10:00 AM – 11:30 AM EDT
Webinar
About the event
Institute leadership and a panel of external experts will discuss these trends:
- New drug approvals and launches: The significance of the growth of novel active substances (NASs) and first-in-class launches.
- R&D pipeline: Products in active development are up 68% over 2016, while precision medicine is dominating in oncology.
- Clinical trial activity: Trial starts are up 14% over 2020 and 19% over 2019.
- Clinical development productivity: The composite success rate across all development phases and therapy areas declined to 5.0% in 2021.
- R&D funding: Venture capital deal activity in the U.S. has accelerated in the past two years and includes more than 500 deals related to COVID-19.
- Emerging biopharmaceutical companies’ contribution to innovation: EBPs are responsible for a record 65% of molecules in the R&D pipeline and originated half of the NASs launched in the U.S. in 2021.
- Accelerators of innovation cycles: Stakeholders are accelerating innovation cycles and bringing scientific breakthroughs to patients faster, which is supported by the FDA.
bottom of page